证券代码：301122 证券简称：采纳股份 公告编号：2025-090 关于使用部分闲置自有资金进行现金管理的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 采纳科技股份有限公司（以下简称"公司"）召开的第三届董事会第十二次 会议、第三届监事会第十一次会议、2025 年第一次临时股东大会，分别审议通 过了《关于使用部分闲置募集资金和自有资金进行现金管理的议案》，同意公司 及全资子公司在确保不影响募集资金投资项目和公司正常经营，并有效控制风险 的前提下，使用额度不超过人民币 20,000 万元（含本数）的闲置募集资金（含 超募资金）和额度不超过人民币 80,000 万元（含本数）的自有资金进行现金管 理。使用期限自股东大会审议通过之日起 12 个月内有效。在上述额度和期限内， 资金可循环滚动使用。 同时，在额度范围内授权公司管理层行使相关投资决策权并签署相关文件， 具 体 由 公 司 财 务 部 负 责 组 织 实 施 。 具 体 内 容 详 见 公 司 在 巨 潮 资 讯 网 （www.cninfo.com.cn）披露的相关公告。 注：公司与上述受托方无 ...

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 采纳科技股份有限公司（以下简称"公司"）全资子公司安纳医疗（江苏） 有限公司（以下简称"安纳医疗"），于近日收到国家知识产权局颁发的专利证 书，具体情况如下： | 序号 | 专利名称 | 专利类型 | 专利号 | 专利权人 | 授权公告日 | | --- | --- | --- | --- | --- | --- | | 1 | 唾液采集器 | 外观设计 | ZL | 安纳医疗 | 2025年11月 | | | | | 202530112372.2 | | 4 日 | 上述专利为公司自主研发，其所涉及技术均与公司主营业务产品技术相关， 专利权自授权公告之日起生效。 证券代码：301122 证券简称：采纳股份 公告编号：2025-091 采纳科技股份有限公司 关于全资子公司取得专利证书的公告 上述专利的取得和运用，不会对公司短期的经营业绩构成重大影响，但有利 于公司进一步完善知识产权保护体系，形成持续创新机制，保持技术的领先地位， 提升公司的核心竞争力。 特此公告。 采纳科技股份有限公司董事会 1 / 1 2025 ...

Core Viewpoint - The company, Canar Medical, has seen a significant increase in stock price and trading volume, benefiting from the depreciation of the RMB and its focus on the medical device sector, particularly in assisted reproduction and laboratory consumables [1][2][3]. Group 1: Company Overview - Canar Medical Co., Ltd. specializes in the research, production, and sales of medical and veterinary injection and puncture devices, as well as laboratory consumables [7]. - The company's main products include injection syringes (45.17% of revenue), puncture needles (45.01%), laboratory consumables (5.49%), and others (4.33%) [7]. - Canar Medical began supplying IVF culture tubes to Thermo Fisher in 2018, indicating a strategic partnership in the assisted reproduction market [2]. Group 2: Financial Performance - For the period from January to September 2025, Canar Medical reported a revenue of 246 million, a year-on-year decrease of 15.86%, and a net profit attributable to shareholders of 8.25 million, down 85.64% year-on-year [7]. - As of October 20, the number of shareholders decreased by 3.61% to 7,547, while the average circulating shares per person increased by 3.75% to 10,022 shares [7]. - The company has distributed a total of 155 million in dividends since its A-share listing, with 122 million distributed over the past three years [8]. Group 3: Market Dynamics - The stock price of Canar Medical increased by 4.52% on November 4, with a trading volume of 439 million and a turnover rate of 18.27%, bringing the total market capitalization to 3.933 billion [1]. - The company benefits from a high overseas revenue ratio of 90.61%, which is positively impacted by the depreciation of the RMB [3]. - The average trading cost of the stock is 26.11, with the current price approaching a resistance level of 33.74, indicating potential for upward movement if the resistance is broken [6].

Core Viewpoint - The stock of Caina Co., Ltd. experienced a significant increase, reaching the daily limit of 20% with a turnover rate of 12.03% and a total transaction amount of 259 million yuan [1] Trading Activity - The stock was listed on the Shenzhen Stock Exchange due to a closing price increase of 20.00%, with institutional net purchases amounting to 8.9161 million yuan [1] - The top five trading departments recorded a total transaction of 126 million yuan, with a buying amount of 81.1914 million yuan and a selling amount of 45.1546 million yuan, resulting in a net purchase of 36.0369 million yuan [1] - Among the trading departments, five institutional special seats were involved, with total buying amounts of 42.7724 million yuan and selling amounts of 33.8563 million yuan, leading to a net purchase of 8.9161 million yuan [1] Fund Flow - The stock saw a net inflow of 27.6319 million yuan from main funds, with a significant single order net inflow of 35.3019 million yuan, while large orders experienced a net outflow of 7.6699 million yuan [1] - Over the past five days, the main funds have seen a net inflow of 20.0944 million yuan [1]

Core Viewpoint - The stock of Canar Medical has reached its daily limit, with a trading volume of 259 million yuan and a market capitalization of 3.714 billion yuan, benefiting from the medical device sector and the depreciation of the RMB [1][2]. Company Overview - Canar Medical Co., Ltd. specializes in the research, production, and sales of medical and veterinary injection and puncture devices, as well as laboratory consumables. The main products include puncture needles, syringes, laboratory consumables, and masks [2][8]. - The company began supplying IVF culture tubes to Thermo Fisher in 2018 [3]. - As of the 2024 annual report, overseas revenue accounts for 90.61% of total revenue, benefiting from the depreciation of the RMB [4][8]. - The revenue composition includes 45.17% from syringes, 45.01% from puncture needles, 5.49% from laboratory consumables, and 4.33% from other products [8]. Financial Performance - For the period from January to September 2025, Canar Medical reported a revenue of 246 million yuan, a year-on-year decrease of 15.86%, and a net profit attributable to shareholders of 8.25 million yuan, down 85.64% year-on-year [8]. Market Activity - On the trading day, the net inflow of main funds was 23.37 million yuan, accounting for 0.09% of the total, with a ranking of 10 out of 131 in the industry. This marks the second consecutive day of increased main fund positions [5][6]. - The average trading cost of the stock is 24.66 yuan, with recent accumulation activity noted, although the strength of this accumulation is weak. The current stock price is near a resistance level of 30.38 yuan, indicating potential for a pullback unless this level is broken [7].

Core Insights - The medical device sector experienced a rise of 1.13% on October 31, with Caina Co., Ltd. leading the gains [1] - The Shanghai Composite Index closed at 3954.79, down 0.81%, while the Shenzhen Component Index closed at 13378.21, down 1.14% [1] Medical Device Sector Performance - Caina Co., Ltd. (301122) saw a closing price of 30.38, with a significant increase of 19.98% and a trading volume of 91,000 shares, amounting to a transaction value of 259 million [1] - Spring Medical (688236) closed at 28.88, up 14.47%, with a trading volume of 84,200 shares and a transaction value of 235 million [1] - ZhenDe Medical (603301) closed at 95.00, increasing by 9.07% with a trading volume of 211,900 shares, resulting in a transaction value of 1.951 billion [1] - Other notable performers included TuoJing Life (300642) with an 8.81% increase, and Rejing Bio (688068) with an 8.70% increase [1] Capital Flow Analysis - The medical device sector saw a net inflow of 475 million from institutional investors, while retail investors experienced a net outflow of 108 million [2][3] - Major stocks like Mindray Medical (300760) had a net inflow of 262 million from institutional investors, but a net outflow of 1.27 billion from retail investors [3] - Other stocks such as Furuishi (300049) and Lepu Medical (300003) also showed significant net inflows from institutional investors, indicating strong institutional interest [3]

Core Points - The Shanghai Composite Index closed at 3961.62 points, below the five-day moving average, with a decline of 0.63% [1] - The total trading volume of A-shares reached 157.92 billion yuan [1] - A total of 1180 A-shares have prices that surpassed the five-day moving average, with notable stocks showing significant deviation rates [1] Summary of Stocks with Significant Deviation Rates - 福石控股 (Fushi Holdings) had a price increase of 20.09% and a deviation rate of 14.05% [2] - 采纳股份 (Canal Shares) increased by 17.26% with a deviation rate of 13.65% [2] - 昆工科技 (Kun Industrial Technology) rose by 15.13% and had a deviation rate of 11.29% [2] - 荣信文化 (Rongxin Culture) saw a 20.00% increase with a deviation rate of 10.78% [2] - 斯菱股份 (Siling Shares) increased by 12.84% with a deviation rate of 8.34% [2] - 春立医疗 (Chunli Medical) rose by 14.07% and had a deviation rate of 8.24% [2] - 迈威生物 (Maiwei Biotech) increased by 10.39% with a deviation rate of 7.83% [2] - 卓越新能源 (Zhuoyue New Energy) saw a 9.90% increase with a deviation rate of 7.66% [2] - 达仁堂 (Darentang) increased by 10.01% with a deviation rate of 7.58% [2] - 冠城新材 (Guancheng New Materials) rose by 10.08% with a deviation rate of 7.44% [2] - 益方生物 (Yifang Biotech) increased by 10.16% with a deviation rate of 7.34% [2] - 大众公用 (Dazhong Public Utilities) rose by 10.01% with a deviation rate of 7.17% [2] - 聚杰微纤 (Jujie Microfiber) increased by 9.71% with a deviation rate of 7.17% [2] - 有友食品 (Youyou Food) rose by 10.00% with a deviation rate of 7.13% [2] - 舒泰神 (Shutai Shen) increased by 14.07% with a deviation rate of 6.99% [2] - 中安科 (Zhong An Ke) rose by 9.88% with a deviation rate of 6.97% [2] - 山东出版 (Shandong Publishing) increased by 10.00% with a deviation rate of 6.96% [2] - 华蓝集 (Hualan Group) rose by 8.00% with a deviation rate of 6.92% [2] Additional Stocks with Minor Deviation Rates - 风神股份 (Fengshen Shares) increased by 9.45% with a deviation rate of 6.76% [3] - 博纳影业 (Bona Film) rose by 9.98% with a deviation rate of 6.75% [3]

证券代码：301122 证券简称：采纳股份 公告编号：2025-089 采纳科技股份有限公司 关于使用部分闲置自有资金进行现金管理的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 采纳科技股份有限公司（以下简称"公司"）召开的第三届董事会第十二次 会议、第三届监事会第十一次会议、2025 年第一次临时股东大会，分别审议通 过了《关于使用部分闲置募集资金和自有资金进行现金管理的议案》，同意公司 及全资子公司在确保不影响募集资金投资项目和公司正常经营，并有效控制风险 的前提下，使用额度不超过人民币 20,000 万元（含本数）的闲置募集资金（含 超募资金）和额度不超过人民币 80,000 万元（含本数）的自有资金进行现金管 理。使用期限自股东大会审议通过之日起 12 个月内有效。在上述额度和期限内， 资金可循环滚动使用。 同时，在额度范围内授权公司管理层行使相关投资决策权并签署相关文件， 具 体 由 公 司 财 务 部 负 责 组 织 实 施 。 具 体 内 容 详 见 公 司 在 巨 潮 资 讯 网 （www.cninfo.com.cn）披露的相关公告。 ...

Core Points - New Oriental Education Technology Group announced a cash dividend of $0.06 per share for the fiscal year ending May 31, 2026 [1] - The ex-dividend date is set for November 17, 2025, with the record date on November 18, 2025, and the payment date on December 2, 2025 [1] - The dividend will be paid in US dollars without withholding tax [1] - The company's board of directors has adopted a share repurchase plan, although specific details have not been disclosed [1] - The board includes prominent members such as Yu Minhong, Zhou Chenggang, and independent directors Li Yanhong, Li Tingbin, and Zhuge Yue [1]

Group 1 - The company has announced a cash dividend and share buyback plan as part of its shareholder return program approved in July 2025 for the fiscal year 2026 [1] - The cash dividend will be $0.12 per ordinary share or $1.2 per American Depositary Share (ADS), to be paid in two installments [1] - The total cash dividend amount expected to be distributed in two installments is approximately $190 million [1] Group 2 - To qualify for the first dividend payment, ordinary shareholders must submit all valid share transfer documents by November 18, 2025 [2] - The company plans to repurchase up to $300 million of its ADS or ordinary shares within the next 12 months [2] - The repurchase may occur through various methods, including open market purchases and private negotiations, depending on market conditions and applicable laws [2]